Last reviewed · How we verify
ARM B - durvalumab plus selumetinib
Inhibits MEK1/2, a key component of the MAPK/ERK signaling pathway.
Inhibits MEK1/2, a key component of the MAPK/ERK signaling pathway. Used for Non-small cell lung cancer.
At a glance
| Generic name | ARM B - durvalumab plus selumetinib |
|---|---|
| Also known as | MEDI-4736 plus AZD-6244 |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Anti-PD-L1 antibody and MEK inhibitor |
| Target | PD-L1 and MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Durvalumab is an anti-PD-L1 antibody, while selumetinib is a MEK inhibitor. This combination targets the MAPK/ERK pathway, which is often dysregulated in cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Rash
- Cough
Key clinical trials
- AZD9291 in Combination With Ascending Doses of Novel Therapeutics (PHASE1)
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. (PHASE2)
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: